Component
Gestational diabetes, preeclampsia or preterm birth composite
Gestational diabetes, preeclampsia or preterm birth composite. Species, exposure and limitations are retained in each linked claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
In MYPP, the gestational-diabetes/preeclampsia/preterm-birth composite occurred in 25.0% versus 26.8% (RR 0.93, 95% CI 0.68–1.28; P=0.67).
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/inositol-research/40920401.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "f72221b219fbb1cae0af2c44b123ab1e95c74e0ba9c10f75ed601720b96248a0", "start_char": 0, "end_char": 1949, "text_sha256": "f72221b219fbb1cae0af2c44b123ab1e95c74e0ba9c10f75ed601720b96248a0"}
- experimental_model
- MYPP double-blind multicenter randomized trial
- exposure
- Myo-inositol 2 g plus folic acid 0.2 mg twice daily versus matching folic acid control until delivery
- limitations
- A larger null result for a prespecified composite in PCOS pregnancy; not the same population or endpoint as the 2013 trial. Confidence limits permit benefit or harm of varying sizes.
- nutrient_topic
- Inositol research collection; topical membership is not evidence of a direct dietary effect. · Inositol (stereoisomer family)
- organism
- Homo sapiens
- plain_language
- The larger blinded PCOS-pregnancy trial did not demonstrate a reduction in its main complication outcome.
- primary_references
- [ino-p40920401] Myo-inositol Supplementation to Prevent Pregnancy Complications in Polycystic Ovary Syndrome: A Randomized Clinical Trial. (2025). https://pubmed.ncbi.nlm.nih.gov/40920401/ DOI: 10.1001/jama.2025.13668
- tissue_or_cell_type
- 464 pregnant individuals with PCOS at 13 Dutch hospitals
Inositol: synthesis, signaling, mineral interactions and conditional deficiency (2026-09-17) · lines 1341–1352
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · MYPP double-blind multicenter randomized trial · source_derived_draft · unverified_draft
### ino-gdm-2025 In MYPP, the gestational-diabetes/preeclampsia/preterm-birth composite occurred in 25.0% versus 26.8% (RR 0.93, 95% CI 0.68–1.28; P=0.67). Condition category: normal nutrient_topic: Inositol research collection; topical membership is not evidence of a direct dietary effect. plain_language: The larger blinded PCOS-pregnancy trial did not demonstrate a reduction in its main complication outcome. organism: Homo sapiens tissue_or_cell_type: 464 pregnant individuals with PCOS at 13 Dutch hospitals experimental_model: MYPP double-blind multicenter randomized trial limitations: A larger null result for a prespecified composite in PCOS pregnancy; not the same population or endpoint as the 2013 trial. Confidence limits permit benefit or harm of varying sizes. exposure: Myo-inositol 2 g plus folic acid 0.2 mg twice daily versus matching folic acid control until delivery evidence_span: {"source_cache": "artifacts/inositol-research/40920401.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "f72221b219fbb1cae0af2c44b123ab1e95c74e0ba9c10f75ed601720b96248a0", "start_char": 0, "end_char": 1949, "text_sha256": "f72221b219fbb1cae0af2c44b123ab1e95c74e0ba9c10f75ed601720b96248a0"} [ino-p40920401] Myo-inositol Supplementation to Prevent Pregnancy Complications in Polycystic Ovary Syndrome: A Randomized Clinical Trial. (2025). https://pubmed.ncbi.nlm.nih.gov/40920401/ DOI: 10.1001/jama.2025.13668
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.